Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: SELL (auto-tracking)
-0.55% $25.40
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 371.88 mill |
EPS: | -5.64 |
P/E: | -4.50 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 14.64 mill |
Avg Daily Volume: | 0.0853 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.50 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.02x |
Company: PE -4.50 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
$22.70 (-10.62%) $-2.70 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 24.32 - 26.48 ( +/- 4.25%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Levitz Michael L | Buy | 51 682 | Stock Option (Right to Buy) |
2024-03-15 | Levitz Michael L | Buy | 21 329 | Restricted Stock Unit |
2024-03-15 | Colleran David | Buy | 46 875 | Stock Option (Right to Buy) |
2024-03-15 | Colleran David | Buy | 19 345 | Restricted Stock Unit |
2024-03-15 | Nunes Anne | Buy | 26 442 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
51.56 |
Last 100 transactions |
Buy: 1 044 875 | Sell: 338 384 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $25.40 (-0.55% ) |
Volume | 0.0773 mill |
Avg. Vol. | 0.0853 mill |
% of Avg. Vol | 90.68 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $23.69 | N/A | Active |
---|
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.